The effect of spironolactone on diastolic function in haemodialysis patients.
Diastolic function
E/e’
Echocardiography
HFpEF
Haemodialysis
Spironolactone
Journal
The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
15
09
2020
accepted:
25
01
2021
pubmed:
6
2
2021
medline:
16
10
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent in patients on maintenance haemodialysis (HD) and lacks effective treatment. We investigated the effect of spironolactone on cardiac structure and function with a specific focus on diastolic function parameters. The MiREnDa trial examined the effect of 50 mg spironolactone once daily versus placebo on left ventricular mass index (LVMi) among 97 HD patients during 40 weeks of treatment. In this echocardiographic substudy, diastolic function was assessed using predefined structural and functional parameters including E/e'. Changes in the frequency of HFpEF were analysed using the comprehensive 'HFA-PEFF score'. Complete echocardiographic assessment was available in 65 individuals (59.5 ± 13.0 years, 21.5% female) with preserved left ventricular ejection fraction (LVEF > 50%). At baseline, mean E/e' was 15.2 ± 7.8 and 37 (56.9%) patients fulfilled the criteria of HFpEF according to the HFA-PEFF score. There was no significant difference in mean change of E/e' between the spironolactone group and the placebo group (+ 0.93 ± 5.39 vs. + 1.52 ± 5.94, p = 0.68) or in mean change of left atrial volume index (LAVi) (1.9 ± 12.3 ml/m
Identifiants
pubmed: 33544240
doi: 10.1007/s10554-021-02176-5
pii: 10.1007/s10554-021-02176-5
pmc: PMC8255262
doi:
Substances chimiques
Spironolactone
27O7W4T232
Banques de données
ClinicalTrials.gov
['NCT01691053']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1927-1936Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KG1202
Investigateurs
Susanne Berweck
(S)
Patrick Biggar
(P)
Christoph Blaser
(C)
Thomas Bochannek
(T)
Frank Breunig
(F)
Michael Brunner
(M)
Beatrix Büschges-Seraphin
(B)
Stefan Büttner
(S)
Ahmet Cakmak
(A)
Thomas Döltz
(T)
Mara Dörken
(M)
Kai-Uwe Eckardt
(KU)
Heribert Fink
(H)
Stefan Fischer
(S)
Wolfgang Freisinger
(W)
Tilo Freiwald
(T)
Julian Gebhardt
(J)
Helmut Geiger
(H)
Rüdiger Götz
(R)
Jan Goßmann
(J)
Renate Hammerstingl
(R)
Joanna Harazny
(J)
Michael Heckel
(M)
Andrea Heyd-Schramm
(A)
Joachim Hoyer
(J)
Rolf Janka
(R)
Oliver Jung
(O)
Markus Ketteler
(M)
Christina Klaeffling
(C)
Claudius Kleinert
(C)
Marianne Kleinert
(M)
Arnfried Klingbeil
(A)
Thorsten Klink
(T)
Benjamin-Florian Koch
(BF)
Judith Kosowski
(J)
Michael Leidig
(M)
Jens Lutz
(J)
Mohamed Marwan
(M)
Maria Moritz
(M)
Brigitte Moye
(B)
Holger Naujoks
(H)
Kai-Olaf Netzer
(KO)
Ulrike Raff
(U)
Clemens Reichert
(C)
Imke Reimer
(I)
Jurij Ribel
(J)
Sophie Richter
(S)
Christian Ritter
(C)
Sarah Rudolf
(S)
Beate Schamberger
(B)
Michael Schmid
(M)
Thomas Schmiedeke
(T)
Andreas Schmitt
(A)
Heike Schneider
(H)
Reinhard Schneider
(R)
Cord Schneuzer
(C)
Markus Schöffauer
(M)
Lothar Schramm
(L)
Sabine Schütterle
(S)
Susanne Schwedler
(S)
Ewelina Sobkowiak
(E)
Daniel Sollinger
(D)
Frank Strutz
(F)
Sebastian Toncar
(S)
Vladimir Vasiljuk
(V)
Thomas Vogl
(T)
Thorsten Walther
(T)
Julia Weinmann-Menke
(J)
Bettina Wirth
(B)
Hendrick Witsch
(H)
Paul Würmell
(P)
Raoul Zeltner
(R)
Josef Zimmermann
(J)
Références
McCullough PA, Roberts WC (2016) Influence of chronic renal failure on cardiac structure. J Am Coll Cardiol 67(10):1183–1185. https://doi.org/10.1016/j.jacc.2015.11.065
doi: 10.1016/j.jacc.2015.11.065
pubmed: 26965539
Antlanger M, Aschauer S, Kopecky C, Hecking M, Kovarik JJ, Werzowa J, Mascherbauer J, Genser B, Saemann MD, Bonderman D (2017) Heart failure with preserved and reduced ejection fraction in hemodialysis patients: prevalence, disease prediction and prognosis. Kidney Blood Press Res 42(1):165–176. https://doi.org/10.1159/000473868
doi: 10.1159/000473868
pubmed: 28395286
Han JH, Han JS, Kim EJ, Doh FM, Koo HM, Kim CH, Lee MJ, Oh HJ, Park JT, Han SH, Ryu DR, Yoo TH, Kang SW (2015) Diastolic dysfunction is an independent predictor of cardiovascular events in incident dialysis patients with preserved systolic function. PLoS ONE 10(3):e0118694. https://doi.org/10.1371/journal.pone.0118694
doi: 10.1371/journal.pone.0118694
pubmed: 25739020
pmcid: 4349827
Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32(6):670–679. https://doi.org/10.1093/eurheartj/ehq426
doi: 10.1093/eurheartj/ehq426
pubmed: 21138935
Edelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Dungen HD, Pilz S, Binder L, Stahrenberg R, Schmidt A, Marz W, Pieske B (2012) Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 33(2):203–212. https://doi.org/10.1093/eurheartj/ehr292
doi: 10.1093/eurheartj/ehr292
pubmed: 21856682
Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M (2005) Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112(19):2940–2945. https://doi.org/10.1161/CIRCULATIONAHA.105.571653
doi: 10.1161/CIRCULATIONAHA.105.571653
pubmed: 16275882
Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O’Moore-Sullivan T, Marwick TH (2011) A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 4(12):1239–1249. https://doi.org/10.1016/j.jcmg.2011.08.014
doi: 10.1016/j.jcmg.2011.08.014
pubmed: 22172779
Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110(5):558–565. https://doi.org/10.1161/01.CIR.0000138680.89536.A9
doi: 10.1161/01.CIR.0000138680.89536.A9
pubmed: 15277317
Weber KT (2001) Aldosterone in congestive heart failure. N Engl J Med 345(23):1689–1697. https://doi.org/10.1056/NEJMra000050
doi: 10.1056/NEJMra000050
pubmed: 11759649
Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309(8):781–791. https://doi.org/10.1001/jama.2013.905
doi: 10.1001/jama.2013.905
pubmed: 23443441
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators T (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392. https://doi.org/10.1056/NEJMoa1313731
doi: 10.1056/NEJMoa1313731
pubmed: 24716680
Charytan DM, Himmelfarb J, Ikizler TA, Raj DS, Hsu JY, Landis JR, Anderson AH, Hung AM, Mehrotra R, Sharma S, Weiner DE, Williams M, DiCarli M, Skali H, Kimmel PL, Kliger AS, Dember LM, Hemodialysis Novel Therapies C (2019) Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int 95(4):973–982. https://doi.org/10.1016/j.kint.2018.08.034
doi: 10.1016/j.kint.2018.08.034
pubmed: 30473139
Chawla LS, Herzog CA, Costanzo MR, Tumlin J, Kellum JA, McCullough PA, Ronco C, Workgroup AX (2014) Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. J Am Coll Cardiol 63(13):1246–1252. https://doi.org/10.1016/j.jacc.2014.01.020
doi: 10.1016/j.jacc.2014.01.020
pubmed: 24530671
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Alexandru Popescu B, Waggoner AD, Houston T, Oslo N, Phoenix A, Nashville T, Hamilton OC, Uppsala S, Ghent LB, Cleveland O, Novara I, Rochester M, Bucharest R, St. Louis M (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 17(12):1321–1360. https://doi.org/10.1093/ehjci/jew082
doi: 10.1093/ehjci/jew082
pubmed: 27422899
Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40(40):3297–3317. https://doi.org/10.1093/eurheartj/ehz641
doi: 10.1093/eurheartj/ehz641
pubmed: 31504452
Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ (2006) Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. J Am Soc Echocardiogr 19(3):266–273. https://doi.org/10.1016/j.echo.2005.10.006
doi: 10.1016/j.echo.2005.10.006
pubmed: 16500488
Malik J, Kudlicka J, Valerianova A, Kovarova L, Kmentova T, Lachmanova J (2019) Diastolic dysfunction in asymptomatic hemodialysis patients in the light of the current echocardiographic guidelines. Int J Cardiovasc Imaging 35(2):313–317. https://doi.org/10.1007/s10554-019-01564-2
doi: 10.1007/s10554-019-01564-2
pubmed: 30815807
Huang WM, Lin YP, Chen CH, Yu WC (2019) Tissue Doppler imaging predicts outcomes in hemodialysis patients with preserved left ventricular function. J Chin Med Assoc 82(5):351–355. https://doi.org/10.1097/JCMA.0000000000000078
doi: 10.1097/JCMA.0000000000000078
pubmed: 30893250
Hammer F, Krane V, Stork S, Roser C, Hofmann K, Pollak N, Allolio B, Wanner C (2014) Rationale and design of the mineralocorticoid receptor antagonists in end-stage renal disease study (MiREnDa). Nephrol Dial Transplant 29(2):400–405. https://doi.org/10.1093/ndt/gft409
doi: 10.1093/ndt/gft409
pubmed: 24166468
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing G, American Society of Echocardiography’s G, Standards C, European Association of E (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18(12):1440–1463. https://doi.org/10.1016/j.echo.2005.10.005
doi: 10.1016/j.echo.2005.10.005
pubmed: 16376782
Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317(17):1098–1098. https://doi.org/10.1056/nejm198710223171717
doi: 10.1056/nejm198710223171717
pubmed: 3657876
Khan MA, Yang EY, Zhan Y, Judd RM, Chan W, Nabi F, Heitner JF, Kim RJ, Klem I, Nagueh SF, Shah DJ (2019) Association of left atrial volume index and all-cause mortality in patients referred for routine cardiovascular magnetic resonance: a multicenter study. J Cardiovasc Magn Reson 21(1):4. https://doi.org/10.1186/s12968-018-0517-0
doi: 10.1186/s12968-018-0517-0
pubmed: 30612579
pmcid: 6322235
Kosmala W, Rojek A, Przewlocka-Kosmala M, Wright L, Mysiak A, Marwick TH (2016) Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 68(17):1823–1834. https://doi.org/10.1016/j.jacc.2016.07.763
doi: 10.1016/j.jacc.2016.07.763
pubmed: 27765184
Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre-Amione G, Deswal A (2014) Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail 20(8):560–568. https://doi.org/10.1016/j.cardfail.2014.05.010
doi: 10.1016/j.cardfail.2014.05.010
pubmed: 24905296
Upadhya B, Hundley WG, Brubaker PH, Morgan TM, Stewart KP, Kitzman DW (2017) Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. J Am Geriatr Soc 65(11):2374–2382. https://doi.org/10.1111/jgs.14940
doi: 10.1111/jgs.14940
pubmed: 28542926
pmcid: 5681414
de Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL (2017) Spironolactone metabolites in TOPCAT — new insights into regional variation. N Engl J Med 376(17):1690–1692. https://doi.org/10.1056/NEJMc1612601
doi: 10.1056/NEJMc1612601
pubmed: 28445660
pmcid: 5590224
Hammer F, Malzahn U, Donhauser J, Betz C, Schneider MP, Grupp C, Pollak N, Stork S, Wanner C, Krane V, Mi RSG (2019) A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int 95(4):983–991. https://doi.org/10.1016/j.kint.2018.11.025
doi: 10.1016/j.kint.2018.11.025
pubmed: 30712923
Malik J, Lachmanova J, Kudlicka J, Rocinova K, Valerianova A, Bartkova M, Tesar V (2016) Left atrial dysfunction in end-stage renal disease patients treated by hemodialysis. Nephron 133(3):169–174. https://doi.org/10.1159/000447500
doi: 10.1159/000447500
pubmed: 27344674
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O’Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD (2014) Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 7(5):740–751. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001583
doi: 10.1161/CIRCHEARTFAILURE.114.001583
pubmed: 25122186
pmcid: 4916914
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD (2015) Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 132(5):402–414. https://doi.org/10.1161/CIRCULATIONAHA.115.015884
doi: 10.1161/CIRCULATIONAHA.115.015884
pubmed: 26130119
pmcid: 4526442
Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK (2008) Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 3(6):1644–1651. https://doi.org/10.2215/cjn.00850208
doi: 10.2215/cjn.00850208
pubmed: 18632852
pmcid: 2572269
Booth J, Pinney J, Davenport A (2010) N-terminal proBNP–marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? Clin J Am Soc Nephrol 5(6):1036–1040. https://doi.org/10.2215/CJN.09001209
doi: 10.2215/CJN.09001209
pubmed: 20507952
pmcid: 2879314